USPTO Examiner GOTFREDSON GAREN - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18822564Dry Powdered FormulationsSeptember 2024August 2025Abandon1111NoNo
18639137ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONSApril 2024March 2026Abandon2320YesNo
18410155EVA SEGMENTED INTRAVAGINAL RINGS CONTAINING PROGESTERONEJanuary 2024December 2025Abandon2420NoNo
18515201METHOD FOR PREPARING POLY(THIOCTIC ACID)-COPPER COATING ON SURFACE OF CARDIOVASCULAR STENT MATERIALNovember 2023November 2025Allow2300NoNo
18506493SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USENovember 2023June 2024Allow710NoNo
18483098FREEZE-DRIED ARIPIPRAZOLE FORMULATIONOctober 2023January 2025Abandon1610NoNo
18477212METHOD FOR SKIN PROTECTION BY USING A ZnO/NSP COMPOSITESeptember 2023October 2025Allow2500NoNo
18364862COMPRESSED NICOTINE LOZENGEAugust 2023August 2025Allow2520YesNo
18345770NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERYJune 2023March 2025Allow2010NoNo
18339800COMPOSITIONS FOR COATING EDIBLE SUBSTRATES AND METHODS OF MAKING AND USING THE SAMEJune 2023June 2025Abandon2420NoNo
18338382RAPAMYCIN FOR INCREASED MILK PRODUCTIONJune 2023February 2026Abandon3210NoNo
18329422COMPOUND, PRODUCTION METHOD THEREFOR, AND HYDROGEN SUPPLY METHODJune 2023January 2025Abandon1910NoNo
18254286METHOD FOR PREPARATION OF EFFERVESCENT GRANULESMay 2023September 2024Allow1620NoNo
18253766CONTROLLED ENTRAPMENT AND RELEASE OF MOLECULAR CARGOMay 2023June 2024Allow1311YesNo
18251744METHOD FOR PREPARING BIODEGRADABLE MICROCAPSULES AND MICROCAPSULES THUS OBTAINEDMay 2023January 2026Allow3301NoNo
18043452Zwitterionic Hydrogels and Methods of Making and Using Same for Protein TherapyFebruary 2023January 2026Abandon3510NoNo
18108576METHOD OF MANUFACTURING SPRAY-DRIED POWDERSFebruary 2023May 2025Allow2711NoNo
18151604SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USEJanuary 2023April 2024Abandon1500NoNo
18147254HYDROGEN SUPPLY MATERIAL AND PRODUCTION METHOD THEREFOR, AND HYDROGEN SUPPLY METHODDecember 2022January 2025Abandon2410NoNo
18009373COMPOSITION COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENTDecember 2022October 2025Allow3410NoNo
18059475INSECT AND NON-INSECT ARTHROPOD PEST REPELLENT COMPOSITIONS AND METHODSNovember 2022February 2025Abandon2611NoNo
17930261SIMETHICONE CHEWABLE COMPOSITIONSeptember 2022June 2024Allow2140YesNo
17884045FORMULATIONS OF MAZINDOLAugust 2022July 2025Abandon3510NoNo
17793476DEODORANT COMPOSITIONJuly 2022July 2025Abandon3610NoNo
17792843STARCH FILM-FORMING COMPOSITIONS AND METHODS OF THEIR USE FOR PREPARING CAPSULE SHELLSJuly 2022January 2026Allow4211NoNo
17791324Joint Health Composition and Use Thereof in Healthy MammalsJuly 2022September 2025Abandon3901NoNo
17857959MONOLITHIC INTRAVAGINAL RINGS COMPRISING PROGESTERONE AND METHODS OF MAKING AND USES THEREOFJuly 2022August 2024Abandon2610NoNo
17785666GLUTATHIONE-CONTAINING COMPOSITIONJune 2022May 2025Abandon3610NoNo
17782067CAPSULE WITH REDUCED POWDER LEAKAGEJune 2022December 2025Allow4211NoNo
17829702SUSTAINED RELEASE ESTROGEN VAGINAL RING PESSARY FOR TREATMENT OF ATROPHY, CYSTITIS AND UTEROVAGINAL PROLAPSEJune 2022August 2023Allow1421NoNo
17777566AN ANTIPERSPIRANT COMPOSITIONMay 2022October 2025Allow4111NoNo
17740878METHODS AND ARTICLES FOR ALLERGIC DESENSITIZATION VIA THE ORAL MUCOSAMay 2022August 2025Abandon3930NoNo
17769679A STABLE EFFERVESCENT CO-PROCESSED EXCIPIENT COMPOSITION AND A PROCESS FOR PREPARING THE SAMEApril 2022June 2025Abandon3801NoNo
17714769COMPOSITION FOR PREVENTING, INHIBITING OR TREATING INFECTION OF CORONAVIRUSApril 2022November 2024Abandon3120NoNo
17710491MEDICAL DEVICE WITH A BIOCOMPATIBLE COATINGMarch 2022May 2025Abandon3830NoNo
17691660LIQUID DRESSINGMarch 2022January 2026Allow4621NoNo
17691897Bellows Bandage Drug Delivery SystemMarch 2022May 2024Allow2610NoNo
17691911SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANEMarch 2022August 2024Abandon3010NoNo
17685644COMPOSITION AND METHODS FOR GENERATING AND SUSTAINING MOLECULAR HYDROGEN (H2) IN AQUEOUS SYSTEMSMarch 2022June 2024Allow2810NoNo
17680657Polyurethane Based Medical ArticlesFebruary 2022January 2025Allow3521NoNo
17637884MICROENCAPSULATED PROBIOTIC AND COMPOSITIONS CONTAINING THE SAMEFebruary 2022May 2025Abandon3901NoNo
17676822PHARMACEUTICAL COMPOSITION OF LIPID NANOPARTICLE FOR DELIVERING NUCLEIC ACID DRUG CONTAINING TREHALOSE DERIVATIVE AND NOVEL STRUCTURE-MAINTAINING LIPID COMPOUNDFebruary 2022June 2025Allow4011YesNo
17636105COMPOSITION FOR TREATMENT OF BURN WITH SCAR REMOVALFebruary 2022April 2025Abandon3810NoNo
17580991TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMSJanuary 2022February 2024Abandon2510NoNo
17580180DISSOLVABLE SOLID ARTICLE CONTAINING PRESERVATIVESJanuary 2022February 2025Allow3740YesNo
17597601DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURADJanuary 2022February 2025Abandon3701NoNo
17623528COLLAGEN POLYSACCHARIDE WOUND DRESSINGDecember 2021April 2025Abandon4001NoNo
17621319POULTRY FEED AND DRINKING WATER COMPOSITION COMPRISING MONOMETHYLSILANETRIOLDecember 2021October 2025Abandon4620NoNo
17549151CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCESDecember 2021March 2024Abandon2710NoNo
17545490FASTING MIMICKING KETOGENIC DIET TO IMPROVE IMMUNE FUNCTION AND VACCINE RESPONSE AND MINIMIZE RISK IN ADULTS AND ELDERLYDecember 2021March 2025Abandon3921NoNo
17540929NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERYDecember 2021June 2023Allow1941YesNo
17539611SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USEDecember 2021January 2023Allow1322NoNo
17613023COPOLYMERS FOR STABILIZING EMULSIONS AND/OR FORMING INTERFACIAL FILMS, AND METHODS THEREOFNovember 2021March 2025Allow4011NoNo
17453468THERAPEUTIC PH RESPONSIVE COMPOSITIONSNovember 2021June 2024Allow3211NoNo
17516745Low Surfactant Personal Care CompositionsNovember 2021March 2026Abandon5231NoYes
176077395-AMINOLEVULINIC ACID FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASEOctober 2021November 2024Abandon3611NoNo
17512937COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING CEREBROVASCULAR DISEASE COMPRISING MELITTIN OR MAGNETIC IRON OXIDE NANOPARTICLE LOADED WITH MELITTIN AS EFFECTIVE COMPONENTOctober 2021October 2025Abandon4850NoNo
17507151BIMODAL TREATMENT METHODS AND COMPOSITIONS FOR GASTROINTESTINAL LESIONS WITH ACTIVE BLEEDINGOctober 2021June 2024Allow3211NoNo
17448862FREEZE-DRIED ARIPIPRAZOLE FORMULATIONSeptember 2021November 2023Abandon2610NoNo
17478051ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOFSeptember 2021May 2025Abandon4420NoYes
17477644MULTIFUNCTIONAL (METH)ACRYLATE POLYSACCHARIDE MICROCAPSULESSeptember 2021December 2024Abandon3921NoNo
17409946DEODORANT COMPOSITIONS WITH METAL OXIDESAugust 2021July 2024Allow3521YesNo
17430521COMPARTMENTALIZED DRUG DELIVERY DEVICESAugust 2021October 2024Abandon3801NoNo
17397820METHODS FOR TREATING RESPIRATORY VIRAL INFECTIONSAugust 2021February 2025Allow4231YesNo
17394446FLEXIBLE, POROUS, DISSOLVABLE SOLID SHEET ARTICLE CONTAINING DIRECT-ADDED MICROCAPSULES AND PROCESS FOR MAKING THE SAMEAugust 2021March 2025Allow4331NoNo
17390185PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTSJuly 2021November 2025Allow5161YesYes
17380509CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCESJuly 2021September 2021Allow200NoNo
17373070SALICYLIC ACID GELJuly 2021February 2025Allow4321YesNo
17367786Oral Care Composition Indicative Of Proper Tooth CleaningJuly 2021August 2023Abandon2510NoNo
17362291PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONSJune 2021August 2023Abandon2510NoNo
17414510POWDER, WOUND-COVERING MATERIAL, ADHESION PREVENTION MATERIAL, HEMOSTATIC MATERIAL, AND PRODUCTION METHOD FOR POWDERJune 2021May 2025Allow4721NoNo
17413715WOUND DRESSINGS INCLUDING PVP-CITRIC ACID COPOLYMERJune 2021November 2025Abandon5320YesNo
17334537LIQUID GRIP LOTIONMay 2021December 2022Abandon1910NoNo
17332277METHOD OF MAKING COMPOSITION INCLUDING ENCAPSULATED CAFFEINEMay 2021March 2026Allow5861YesNo
17307755METHOD FOR PRODUCING SILICA PARTICLES AND THEIR USE IN COSMETIC COMPOSITIONSMay 2021December 2025Allow5541NoNo
17286226COATING METHODApril 2021November 2024Abandon4321NoNo
17230069METHOD OF PREVENTING OR TREATING VIRAL INFECTIONSApril 2021September 2025Allow5360YesNo
17224781CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCESApril 2021June 2021Allow300NoNo
17222343Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving AgentApril 2021March 2024Allow3620NoNo
17217060PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORSMarch 2021February 2024Abandon3421NoNo
17301237Personal Care Compositions Comprising Cannabidiol and LicoriceMarch 2021March 2026Allow5940NoYes
17216148Personal Care CompositionsMarch 2021December 2025Allow5751NoNo
17210765COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAMEMarch 2021April 2025Abandon4940NoNo
17210408Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of ManufactureMarch 2021December 2023Abandon3320NoNo
17209288ANTIPERSPIRANT AND DEODORANT COMPOSITIONS FOR INCREASED SKIN LUBRICITYMarch 2021July 2025Allow5240NoNo
17202394COMPOSITIONS COMPRISING BENZOYL PEROXIDE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERMarch 2021January 2023Abandon2210NoNo
17193275POLYURETHANE UREA SOLUTIONS FOR COSMETIC COMPOSITIONSMarch 2021February 2024Abandon3620NoNo
17273492COMPOSITIONS AND METHODS FOR APPLICATION OVER SKINMarch 2021November 2024Allow4431NoNo
17191090Topical Composition for and Method of Preventing and Treating Pressure Sores and Skin IrritationMarch 2021October 2024Abandon4330NoNo
17174389NAIL TREATMENT COMPOSITIONFebruary 2021September 2023Abandon3111NoNo
17173671Aloe Mint Scalp WipesFebruary 2021November 2023Abandon3320NoNo
17266048AN ANTIPERSPIRANT COMPOSITIONFebruary 2021September 2022Allow2010NoNo
17156146USE OF BETA-1,3-GLUCAN FOR MODULATING IMMUNE FUNCTION AND TREATING INTESTINAL INFLAMMATIONJanuary 2021July 2023Allow3020NoNo
17262572PHARMACEUTICAL METHODS AND COMPOSITIONSJanuary 2021July 2023Allow3030NoNo
17260375PHARMACEUTICAL COMPOSITIONS WITH A CDC7 INHIBITORJanuary 2021April 2025Abandon5150NoNo
17141003HAIR COLORING COMPOSITIONS AND METHODS THEREOFJanuary 2021September 2023Allow3230YesNo
17136584BONE REPAIR COMPOSITION AND KITDecember 2020July 2024Allow4340YesNo
17253891Gel-In-Oil Emulsion and Transdermally Absorbed AgentDecember 2020December 2022Abandon2310NoNo
17111645COMPOSITIONS AND METHODS FOR MASKING THE TASTE OF DRUGSDecember 2020November 2024Abandon4741YesNo
17111940MAGNESIUM PHOSPHATE HYDROGELSDecember 2020November 2022Allow2400NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOTFREDSON, GAREN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
27
(84.4%)
Examiner Reversed
5
(15.6%)
Reversal Percentile
27.3%
Lower than average

What This Means

With a 15.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
102
Allowed After Appeal Filing
17
(16.7%)
Not Allowed After Appeal Filing
85
(83.3%)
Filing Benefit Percentile
19.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GOTFREDSON, GAREN - Prosecution Strategy Guide

Executive Summary

Examiner GOTFREDSON, GAREN works in Art Unit 1619 and has examined 538 patent applications in our dataset. With an allowance rate of 40.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner GOTFREDSON, GAREN's allowance rate of 40.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GOTFREDSON, GAREN receive 3.09 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GOTFREDSON, GAREN is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.2% benefit to allowance rate for applications examined by GOTFREDSON, GAREN. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.0% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.7% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 52.9% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 58.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.